6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-INR-17012013	2017-09-01	2017-07-17	Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease	Clinical study of botulinum toxin type A in the treatment of depressive symptoms in patients with Parkinson's disease	Parkinson‘s disease, Depression	BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;	Shanghai Tongji Hospital, Tongji University	NULL	Pending	18	80	Both	BTX-A:40;Placebo:40;		China
2	NCT01313845 (ClinicalTrials.gov)	February 2011	10/3/2011	Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease	Randomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's Disease	Parkinson's Disease	Drug: amantadine sulfate;Drug: 0.9% sodium chloride	Jee-Young Lee	Seoul National University Boramae Hospital;Samsung Medical Center;Seoul National University Bundang Hospital;Hanyang University	Completed	30 Years	79 Years	Both	46	Phase 4	Korea, Republic of
3	NCT00623363 (ClinicalTrials.gov)	April 2007	2/1/2008	Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease		Parkinson's Disease	Drug: piclozotan;Drug: 0.9% sodium chloride (normal saline)	Asubio Pharmaceuticals, Inc.	NULL	Completed	40 Years	85 Years	Both	27	Phase 2	United States;Guatemala;Romania